InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (3 ops.)
Explore the complete record of transactions filed by PRASAD SUYASH, Directeur Médical et Responsable de la R&D. Officer active across 2 companies, notably Taysha Gene Therapies, Inc.. Cumulatively, 3 reports have been published. Total volume traded: €1.4m. The latest transaction was disclosed on 29 June 2022 (Cession). Regulator: SEC (Form 4). All data is free.
Declarations3 total
€44,94712,324 shares@ €3.64710.0026% mcap3.1% of flow
Common Stock
SEC:0001209191-22-040356:0·
€699,23935,056 shares@ €19.9463100.0% of flow
Common Stock
SEC:0001209191-21-044563·
€699,23935,056 shares@ €19.94630.041% mcap48.4% of flow
Common Stock
SEC:0001209191-21-044563:0·
3 of 3 declarations
About PRASAD SUYASH
Suyash Prasad is the Chief Medical Officer and Head of R&D at Taysha Gene Therapies, Inc. He is responsible for overseeing research and development initiatives for gene therapies. Suyash plays a key role in innovation and advancing treatments aimed at improving patient outcomes. His expertise in medicine and biotechnology is essential for advancing Taysha's mission in the field of gene therapies.
